NUVARING 0.120mg / 0.015mg/24h vaginal delivery system medication leaflet

G02BB01 • etonogestrel + ethinylestradiol • Genito urinary system and sex hormones | Contraceptives for topical use | Intravaginal contraceptives

Etonogestrel and ethinylestradiol are used together in combined hormonal contraceptives, particularly in the form of a contraceptive vaginal ring. This combination contains a progestin (etonogestrel) and a synthetic estrogen (ethinylestradiol), which work synergistically to prevent pregnancy by inhibiting ovulation, altering cervical mucus, and thinning the endometrium, thereby preventing the implantation of a fertilized egg.

Etonogestrel is a newer-generation progestin derived from desogestrel, providing effective contraceptive protection and having antiandrogenic properties, which may help reduce acne and seborrhea. Ethinylestradiol stabilizes the menstrual cycle and contributes to contraceptive efficacy. The vaginal ring containing this combination releases consistent doses of hormones, offering monthly contraceptive protection and serving as a convenient option for women seeking a reversible and easy-to-use method.

While this combination is effective, its use may cause side effects. The most common include nausea, headaches, breast tenderness, intermenstrual bleeding, and mood changes. In rare cases, more serious reactions may occur, such as venous thromboembolism, high blood pressure, or liver disorders. Women who smoke, especially those over 35 years old, are at an increased risk of cardiovascular complications.

This combination should be used as directed by a doctor, and the patient should follow the prescribed schedule for using the vaginal ring (typically 3 weeks of use followed by a 1-week break). Regular medical check-ups are important to monitor for potential side effects and assess overall health. If severe side effects occur, such as chest pain, difficulty breathing, or severe leg pain, immediate medical attention is necessary.